LBX-200 is under clinical development by Liberyx Therapeutics and currently in Phase I for Inherited Metabolic Disorders. According to GlobalData, Phase I drugs for Inherited Metabolic Disorders have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LBX-200’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

LBX-200 overview

LBX-200 is under development for the treatment of glycine encephalopathy also known as non-ketonic hyperglycinemia (NKH). The drug candidate is a new chemical entity. It acts by targeting peroxisome proliferator-activated receptor alpha. It is being developed based on Curyx platform.

Liberyx Therapeutics overview

Liberyx Therapeutics is a pharmaceuticals and healthcare company which is engaged to offer clinical trials in the fields of highly unmet orphan diseases which affects the children where no immediate vaccination is available. Liberyx Therapeutics is headquartered in Kowloon, Hong Kong.

For a complete picture of LBX-200’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.